Genethon is a life sciences. Over the past three years, Genethon has been involved in 3 licensing and acquisition transactions, with a primary focus on Gene Therapy (6 deals). The company currently has 6 active clinical trials, primarily in Rare Disease.
Deals (12mo)
1
Active Trials
6
Top Modality
Gene Therapy
Focus Area
Rare Disease
Licensing, acquisition, and partnership transactions involving Genethon in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| AB-1009 | AskBio | Gene Therapy | Unknown | license | Apr 2026 |
| AB-1009 | Bayer | Gene Therapy | Phase 1 | license | Apr 2026 |
| AB-1009 | AskBio | Gene Therapy | Unknown | license | Apr 2026 |
Therapeutic areas and modalities where Genethon is most active based on deal history and clinical trial data.
Key indicators of Genethon's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Genethon has 6 active clinical trials across 4 development phases.
1
Unknown
1
Not Applicable
3
Phase 1
1
Phase 2
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Genethon is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Genethon ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Genethon include Rare Disease (6 deals and trials), and Rare Disease (1 deal and trial). In terms of modality, Genethon has shown particular interest in gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Genethon and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Genethon's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
Industry-wide analysis of deal terms, trends, and market dynamics
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 3,000+ real biopharma licensing deals